T1000	Speculation 1475 1483	suggests
E1000	Speculation:T1000 Scope:T1001
T1001	Span 1475 1618	suggests that this third phenyl ring increases the interaction with ER of the 4-phenolic group of the drugs and/or their aminoethoxy side chain
T1002	Speculation 239 242	may
E1001	Speculation:T1002 Scope:T1003
T1003	Span 239 265	may stimulate tumor growth
T1004	Speculation 1681 1691	suggesting
E1002	Speculation:T1004 Scope:T1005
T1005	Span 1681 1795	suggesting that the di-(tri)pheny-lalkene structure is required for promoting the interaction of the chain with ER
T1006	Negation 1649 1656	without
E1003	Negation:T1006 Scope:T1007
T1007	Span 1649 1680	without any biological activity
T1008	Speculation 2022 2032	suggesting
E1004	Speculation:T1008 Scope:T1009
T1009	Span 2022 2060	suggesting specific antitumor activity
T1010	Negation 2010 2012	no
E1005	Negation:T1010 Scope:T1011
T1011	Span 2010 2060	no evidence suggesting specific antitumor activity
T1012	Speculation 2076 2079	may
E1006	Speculation:T1012 Scope:T1013
T1013	Span 2076 2164	may be more easily obtained with estrogens bearing reagents for proteins rather than DNA
T1014	Negation 2149 2160	rather than
E1007	Negation:T1014 Scope:T1015
T1015	Span 2149 2164	rather than DNA
T1016	Speculation 2496 2506	suggesting
E1008	Speculation:T1016 Scope:T1017
T1017	Span 2496 2540	suggesting that ER is involved in its action
